Source: Eur Respir J 2007; 30: 922-927
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Reichenberger F., Voswinckel R., Enke B., Rutsch M., El Fechtali E., Schmehl T., Olschewski H., Schermuly R., Weissmann N., Ghofrani H. A., Grimminger F., Mayer E., Seeger W.. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007; 30: 922-927

Member's Comments

No comment yet.

Related content which might interest you: The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study Source: Eur Respir J 2006; 28: 138-143 Year: 2006 Vasodilator treatment in chronic thromboembolic pulmonary hypertension Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension Year: 2003 Chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – Russian Programme 2017 Year: 2017 Chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – State of the art session: Pulmonary vascular diseases Year: 2018 Chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – ME5 Chronic thromboembolic pulmonary hypertension Year: 2015 Chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (1) 1801915; 10.1183/13993003.01915-2018 Year: 2019 Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 272-282 Year: 2015 Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 23: 595-600 Year: 2004 Effects of sildenafil as a bridge therapy for pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Bosentan for inoperable chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Chronic thromboembolic pulmonary hypertension Source: Annual Congress 2007 - Update on venous thromboembolism Year: 2007 Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Chronic thromboembolic pulmonary hypertension (CTEPH) and beyond Source: Annual Congress 2011 - Ceremony for Pulmonary Arterial Hypertension Award (supported by Actelion) followed by Pulmonary Hypertension in the Clinic Grand Round - an interactive session Year: 2011 Diagnosis of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2017; 26: 160108 Year: 2017 ERS statement on chronic thromboembolic pulmonary hypertension Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension Year: 2021